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Purpose: (1) To define the onset and offset of the blood-pressure-lowering effects
of sodium nitroprusside (SNP) for use in developing instructions for dose titration in
children undergoing a surgical or medical procedure, and (2) to assess the safety of SNP
administration in pediatric patients requiring controlled reduction of blood pressure.
Methods: We conducted a randomized, double-blind, parallel-group, dose-ranging,
effect-controlled, multicenter study of intravenous (IV) infusions of SNP in pediatric
patients<17 years, who required controlled hypotension for at least 2 h while undergoing
a surgical or medical procedure. A blinded SNP dose of 0.3, 1, 2, or 3µg/kg/min
was infused for 30min, followed by open-label administration for at least 90min. Both
infusions were titrated to effect.
Results: The final intent-to-treat group comprised 203 patients. Significant reductions
in mean arterial pressure (MAP) from baseline were observed for all four doses at 20 and
25min after the start of infusion (p ≤ 0.009 and p ≤ 0.010 for each time, respectively).
Overall, 98.5% of the patients achieved the target MAP; 72.9% first achieved the
target MAP during the blinded infusion. The mean infusion rate at target MAP was
1.07µg/kg/min.
Conclusion: We determined that 0.3µg/kg/m is a reasonable starting dose for SNP
in pediatric patients requiring controlled hypotension. The infusion rate can then be
increased to achieve the desired reduction in blood pressure. On the basis of our results,
we found an average infusion rate of 1µg/kg/min might be appropriate. Of note, no
cyanide toxicity was reported, and no measureable cyanide levels were detected in any
blood samples obtained during the study. http://clinicaltrials.gov/show/NCT00135668.
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Introduction
Sodium nitroprusside (SNP) was first discovered in 1850, but
its hypotensive effects were not noticed until 1929. Page et al.
reported its first therapeutic use in 1955 (Page et al., 1955), and
in 1962Moraca et al. were the first to use SNP clinically to induce
deliberate hypotension during surgery (Moraca et al., 1962).
Since then, SNP has been widely used to control blood pressure
in infants and children in the perioperative period, despite the
lack of FDA approval for this age group in the United States.
Sodium nitroprusside is the first medication to gain regulatory
approval through the Best Pharmaceuticals in Children’s Act
(BPCA), which was enacted in 2007.
Two million surgical procedures are performed annually on
children <15 years of age, and general anesthesia is administered
in the vast majority of cases. Controlled hypotension is used
in a select group of patients undergoing certain orthopedic,
neurosurgical, craniofacial, ear-nose-and-throat, and burn
procedures. Controlled hypotension is the stepwise, deliberate
reduction of systemic arterial blood pressure in order to decrease
blood loss and the need for blood transfusion and to improve
visibility in the surgical field.
Blood pressure control in children is also a concern in
the intensive care unit (ICU), where it is often necessary to
manage arterial pressure during periods of acute physiologic
stress, which occurs during and after certain surgical and medical
procedures, such as aortic coarctation repair, pulmonary valve
autograft (Ross) procedures, and solid organ transplantation.
Control of systemic arterial pressure is also indicated in
cases of hypertension associated with renal disease, drug
therapy (corticosteroids and immunosuppressive agents), and
extracorporeal membrane oxygenation (ECMO).
A wide variety of drugs of various therapeutic classes have
been used to induce controlled hypotension in the operating
room and to prevent or treat hypertension in the pediatric ICU.
These drug classes include calcium channel blockers (Tobias
et al., 1996), beta-adrenergic antagonists (Kay et al., 2001),
ganglionic blockers (Du Toit, 1970; Gallagher and Milliken,
1979), inhalation anesthetics (Tobias, 1998), and direct-acting
vasodilators such as nitroglycerin and SNP (Jones and Cole, 1968;
Taylor et al., 1970; Wilson et al., 1971; Tinker and Michenfelder,
1976; Kaplan et al., 1980; Groshong, 1996; Sinaiko, 1996). Despite
the frequency of their use, vasodilating agents have not generally
been systematically studied in children. Sodium nitroprusside is
a direct-acting vasodilator commonly used for blood pressure
control. It induces vascular smooth muscle relaxation via nitric
oxide production. Because SNPmetabolism also liberates cyanide
(CN), CN toxicity is a concern when SNP is infused at high doses
and/or for prolonged periods of time, but there are little data to
inform clinicians of the risks of specific infusion regimens across
pediatric age groups.
We performed a randomized, double-blind, parallel-group,
dose-ranging, effect-controlled, multicenter study examining
the effects of SNP in pediatric patients requiring controlled
hypotension for at least 2 h during a surgical or medical
procedure. Our aim was to establish the starting and maximum
infusion rates that afford optimum blood pressure control and to
develop a safe dosing regimen in children. The specific objectives
were to (1) describe the relationship between the infusion rate of
SNP and changes in blood pressure (2) to define the onset and
offset of blood-pressure-lowering effects of SNP to be used to
provide adequate instructions for dose titration in the pediatric
population undergoing a surgical or medical procedure, and (3)
to assess the safety of SNP administration in pediatric patients
requiring controlled reduction of blood pressure.
Materials and Methods
The study was approved by the IRB at each of the 11 study
research centers before enrollment. Parental informed consent
and subject assent, when applicable, were obtained for all
participants. Subjects were male and female patients, from
birth through 16 years, who required intra-operative deliberate
hypotension for at least 2 h. Enrollment was stratified into 5 age
groups: neonates (<30 days), infants and toddlers (30 days to <2
years), pre-school children (2 to<6 years), school-age children (6
years of age to <Tanner Stage III), and adolescents (Tanner Stage
III through 16 years). Complete inclusion and exclusion criteria
are detailed in Table 1.
The following clinical parameters were carefully outlined
prospectively before beginning patient enrollment: (a)
TABLE 1 | Inclusion and exclusion criteria.
S. No. Inclusion criteria Exclusion criteria
1 Patient was < 17 years of age Patient had a known allergy to SNP
2 Neonates must have been
full-term gestation and have
had a body weight of at least
2.5 kg
Patient had a known mitochondrial
cytopathy with a disorder of
oxidative phosphorylation or of
respiratory chain enzymes
3 Patient required
pharmacologically-induced
hypotension for acute blood
pressure management for
surgery or other invasive
procedure, e.g., cerebral
artery embolization
Patient had a contraindication to
vasodilator therapy for control of
blood pressure during surgery or
procedures
4 Duration of the patient’s
controlled hypotension was
expected to be ≥ 2 h
Patient had participated in other
clinical trials for investigational drugs
and/or devices within 30 days prior
to enrollment
5 Patient required general
anesthesia with endotracheal
intubation or IV sedation
without endotracheal
intubation
Patient had any serious medical
condition which, in the investigator’s
opinion, was likely to interfere with
study procedures
6 Patient required placement of
intra-arterial line during the
surgical or medical procedure
Patient was moribund (death likely to
occur within 48 h)
7 The patient’s parent or legal
guardian gave permission
(informed consent) and patient
gave assent when appropriate
Patient had a positive result for the
urine or serum human chorionic
gonadotropin (HCG) test
administered at screening
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Controlled hypotension was defined as a reduction in mean
arterial blood pressure (MAP) to a target value specified by the
investigator prior to the start of SNP infusion and in keeping
with the clinical presentation and needs of the patient (b) the
screening MAP was defined as the calculated MAP from the
blood pressure recorded at the preoperative visit taken within
14 days of the planned operative or other procedure where
hypotension was required (c) the baseline MAP was defined as
the blood pressure recorded just before the blinded study drug
administration period following at least a 5-min period of stable
anesthesia (no changes in dosages of anesthetic agents) and after
the completing the initial fluid rehydration infusions, and (d) the
minimum target MAP value was 50mmHg for patients≥30 days
of age and 40mmHg for patients <30 days of age.
Previous treatment effects on blood pressure in a pediatric
population suggested that a reasonable parameter estimate was a
nominal 10mmHg between-group difference in the change from
baseline in MAP, with a group standard deviation of 13mmHg.
A minimum of 30 patients per treatment arm was estimated
to be required to detect this difference, with 80% power to
prevent a Type II error (which would incorrectly accept the
null hypothesis that a statistical test would not demonstrate a
treatment difference) and an overall two-sided significance level
(alpha) of 0.05. If a formal interim analysis of the primary study
endpoint was deemed appropriate, alpha levels of 0.03 and 0.02
would be assumed for the interim and final data reviews. On
the basis of these parameters, between 40 and 50 patients per
treatment arm were required. Approximately 200 patients were
recruited during the course of the trial; about half were scheduled
to have completed the trial by 1 year.
For the primary efficacy analysis, we used a last-observation-
carried-forward (LOCF) approach to replace missing values in
the intent-to-treat (ITT) population. For all secondary efficacy
analyses, we used the observed data. For demographic and
baseline characteristics and safety endpoints, we analyzed each
variable using all available data. Patients with missing data were
excluded only from the analyses for which data were not available.
The study was divided into the following four study periods
(see Figure 1):
1. Pre-study drug administration, which encompassed up to 14
days preceding the start of the surgery or procedure. During
this time, informed consent/assent, randomization, and
other enrollment procedures were performed. Demographic
information [gender, age, race, height (length for neonates
and infants), and weight], operative information (e.g.,
preoperative diagnosis and name of surgical or medical
procedure), and screening vital signs were collected.
2. Blinded study drug administration, which began with the
start of study drug administration following stabilization of
anesthesia. During this time, patients were administered a
blinded dose of SNP for up to 30min. To improve the safety
of onset of effect, the blinded dose was initiated at one-third
the full randomized rate for 5min and was then increased
to two-thirds the full rate for 5 additional minutes, after
which time the dose was increased to the full rate if the
target blood pressure was not attained for the final 20min
of the 30-min blinded period. The blinded dose was chosen
from a pre-designed randomization schedule and included
doses of 0.3, 1, 2, and 3mcg/kg/min. Blinded study drug
administration was started either before or after the surgical
incision. If the blinded study drug was initiated before the
incision, administration was also completed prior to incision,
so the incision was not made during the 30-min blinded study
drug administration period. This period ended at the start of
open-label study drug infusion or at the completion of the
blinded infusion, if no open-label study drug was given.
3. Open-label study drug administration, which is also referred to
as the open-label treatment phase (OTP), began with the start
of open-label study drug infusion. This phase lasted at least
90min, during which time SNP was initiated at a dose deemed
appropriate by the investigator and was gradually adjusted
to reach a target MAP defined by the investigator for each
individual patient, in keeping with the clinical presentation
and the needs of the patient. The target MAP was determined
and recorded before infusion of the study drug was initiated
and could not be less than 50mmHg (or 40mmHg for
patients younger than 30 days of age). The OTP ended at
the completion of open-label infusion. In some cases, patients
continued to receive SNP after the period was completed when
it was clinically indicated. In these cases, SNP was considered
concomitant medication and not study drug.
4. Follow-up was started immediately after infusion of the study
drug was concluded and ended after 30 days, during which
FIGURE 1 | Schematic of study flow. PRE, pre-study drug administration period; BTP, blinded treatment phase; BT2, blinded treatment phase II; OTP, open-label
treatment phase. See manuscript text for description of each phase.
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time any serious adverse events (SAEs) were monitored and
recorded.
Results
A total of 203 subjects were enrolled in the ITT group. The
demographics of enrolled subjects are presented in Table 2 and
are listed according to blinded dosing group.
Study participants were classified into one of the following
five categories according to the surgical or medical procedure
performed:
1. Spinal fusion (n = 106, 52.2%).
2. Craniofacial reconstruction (n = 71, 35.0%).
3. Coarctation of the aorta repair (n = 14, 7.0%).
4. Cerebral angiography (n = 4, 2.0%).
5. Other (n = 8, 3.9%).
The primary efficacy parameter was the change from baseline
MAP 30min after initiation of SNP infusion during the blinded
study drug period. A comparison of change from baseline in
MAP across the SNP dose groups is summarized by mean at
baseline after 30min, and change from baseline for the ITT
population (Table 3). This comparison includes an analysis of
within-group differences. For the ITT population, administration
of SNP statistically significantly reduced MAP 30min after the
start of infusion at each of the four SNP doses (p < 0.001).
A dose response was observed for the change in MAP from
baseline 30min after the start of infusion; larger mean reductions
from baseline in MAP were observed with increasing SNP
dose (0.3–2µg/kg/min). Notably, the reductions in MAP from
baseline at the 1-, 2-, and 3-µg/kg/min SNP doses (−17.0,−20.0,
and −16.6mmHg, respectively) were larger than the reduction
observed at the 0.3-µg/kg/min dose (−11mmHg). The mean
MAP over time is presented in Figure 2 for the ITT population.
Figure 2 graphically depicts our finding that all four SNP doses
decreased MAP from baseline, with larger reductions seen with
the 1-, 2-, and 3-µg/kg/min doses compared with the 0.3-
µg/kg/min SNP dose. Figure 2 also demonstrates that increasing
SNP dose produced greater reductions in MAP with increasing
SNP dose (0.3–2µg/kg/min). The stratified age groups all had a
significant reduction in blood pressure during the blinded phase
(infants p < 0.031, preschool p < 0.032, school age p < 0.020,
and adolescent p < 0.026).
We determined the proportion of patients who achieved the
target MAP in each treatment group, as well as the mean infusion
rate at the target MAP. Overall, 98.5% of the patients achieved
the target MAP. The majority of these patients first achieved
target MAP during the blinded study drug period while they
were actively receiving the infusion (72.9%). All of the patients
(100%) in the 1-µg/kg/min and 3-µg/kg/min SNP dose groups
achieved target MAP, and 96 and 98.1% of the patients in the 0.3-
µg/kg/min and 2-µg/kg/min SNP groups achieved target MAP
overall. The mean infusion rate for which the target MAP was
achieved was 1.07µg/kg/min overall.
TABLE 2 | Demographic data displayed by randomized treatment group.
Baseline demography summary
statistic/category descriptor
Treatment group
0.3µg/kg/min (N = 50) 1µg/kg/min (N = 49) 2µg/kg/min (N = 53) 3µg/kg/min (N = 51) Total (N = 203)
AGE AT SCREENING (MONTHS)
Mean ± SD 110.30 ± 75.424 114.74 ± 71.479 114.21 ± 73.864 111.30 ± 76.429 112.64 ± 73.810
Median 143.50 138.40 136.90 143.20 140.30
Min, Max 0.7, 200.8 2.1, 198.0 0.2, 200.1 0.6, 203.8 0.2, 203.8
SEX
Male 14 (28.0%) 21 (42.9%) 20 (37.7%) 19 (37.3%) 74 (36.5%)
Female 36 (72.0%) 28 (57.1%) 33 (62.3%) 32 (62.7%) 129 (63.5%)
ETHNICITY
Hispanic or Latino 11 (22.0%) 11 (22.4%) 12 (22.6%) 13 (25.5%) 47 (23.2%)
Not Hispanic or Latino 39 (78.0%) 38 (77.6%) 41 (77.4%) 38 (74.5%) 156 (76.8%)
Not reported 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Missing 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
RACE
American Indian or Alaska native 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Asian 1 (2.0%) 3 (6.1%) 4 (7.5%) 3 (5.9%) 11 (5.4%)
Black or African American 7 (14.0%) 4 (8.2%) 5 (9.4%) 4 (7.8%) 20 (9.9%)
Native Hawaiian or Other Pacific
Islander
1 (2.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.5%)
White or Caucasian 40 (80.0%) 42 (85.7%) 42 (79.2%) 40 (78.4%) 164 (80.8%)
Other 1 (2.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.5%)
Reported more than one race 2 (4.0%) 2 (4.1%) 2 (3.8%) 1 (2.0%) 7 (3.4%)
Not reported 2 (4.0%) 2 (4.1%) 4 (7.5%) 6 (11.8%) 14 (6.9%)
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TABLE 3 | Primary efficacy—change from baseline in MAP (mm Hg) after 30min double-blinded infusion.
Assessment
endpoint
category
Statistic Treatment
0.3µg/kg/min (N = 50) 1µg/kg/min (N = 49) 2µg/kg/min (N = 53) 3µg/kg/min (N = 51) Total (N = 203)
BASELINE OBSERVED
Mean ± SD 76.3 ± 11.37 76.9 ± 14.50 73.5 ± 11.50 76.3 ± 12.06 75.7 ± 12.37
Median 76.0 74.0 73.0 75.0 75.0
Min, Max 58, 108 55, 120 45, 102 55, 102 45, 120
30min
Mean ± SD 65.3 ± 13.30 59.9 ± 15.43 53.5 ± 12.09 59.6 ± 17.82 59.5 ± 15.28
Median 65.0 58.0 49.0 56.0 58.0
Min, Max 36, 89 40, 123 35, 92 31, 125 31, 125
CHANGE FROM BASELINE
Mean ± SD −11.0± 15.68 −17.0± 12.88 −20.0± 15.95 −16.6± 18.63 −16.2± 16.16
Median −9.5 −19.0 −21.0 −19.0 −18.0
Min, Max −59, 24 −46, 36 −59, 24 −52, 49 −59, 49
Within-group P-value <0.001 <0.001 <0.001 <0.001 <0.001
95% Confidence interval −15.45, −6.55 −20.70, −13.30 −24.38, −15.58 −21.87, −11.39 −18.44, −13.97
Baseline is defined as the data collected closest in time to and just before the initial infusion of SNP.
P-value and 95% confidence interval are based on a paired t-test.
FIGURE 2 | Mean MAP over time for ITT patients for the 30-min blinded
phase.
Safety
The mean total SNP dose was 43.01µg/kg for neonates,
22.81µg/kg for infants, 15.18µg/kg for preschool patients,
18.28µg/kg for elementary school-age patients, and 16.88µg/kg
for adolescents. Because the blinded dose was increased by
graduated amounts, we analyzed the data to assess whether each
age group tolerated the increasing dose and whether a group’s
members achieved the maximum blinded infusion rate. All five
of the neonates (100.0%) received the 1/3, 2/3, and full SNP
dose. All 50 infants (100.0%) received the one-third SNP dose,
92.0% received the two-thirds SNP dose, and 72.0% received the
full SNP dose. All 12 preschool patients (100.0%) received the
one-third SNP dose and two-third SNP dose, and 58.3% received
the full SNP dose. All 43 school-age patients (100.0%) received
the one-third SNP dose, 83.7% received the two-thirds SNP
dose, and 51.2% received the full SNP dose. All 93 adolescents
(100.0%) received the one-third SNP dose, 75.3% received
the two-thirds SNP dose, and 45.2% received the full SNP
dose.
Adverse events were coded using the MedDRA (version 8.1).
Treatment-emergent adverse events (TEAEs) were defined as
follows: an AE first observed after the initiation of the study drug
(blinded or open-label) or a representation of an exacerbation
(usually in severity) of a pre-existing condition observed prior
to treatment. An overall summary of tolerability and AEs is
provided inTable 4. All 203 patients (100.0%) experienced one or
more TEAEs. Eighteen patients (8.9%) experienced one or more
treatment-emergent SAEs, and 166 patients (81.8%) experienced
treatment-related TEAEs (probably or possibly related). These
TEAEs were classified as severe in 97 patients (47.8%), moderate
in 73 patients (36.0%), and mild in 33 patients (16.3%). Sixty-
six patients (32.5%) had at least one TEAE severe enough to lead
to study drug withdrawal, but no patients experienced TEAEs
severe enough to discontinue the study. There were no deaths
during the study.
The most frequently reported TEAEs (>20%) occurred
in the following system organ classes (SOCs): blood and
lymphatic system disorders; gastrointestinal disorders; general
disorders and administration site conditions; injury, poisoning,
and procedural complications; and vascular disorders. The
most frequently reported TEAEs (>20%) were hypotension
(75.4%), pyrexia (35.0%), operative hemorrhage (33.0%),
vomiting (31.5%), nausea (30.5%), hypertension (25.6%), anemia
(24.1%), and rebound hypertension (23.6%). No dose-response
relationship was apparent for TEAEs, because all patients in
each of the four SNP dose groups experienced at least one TEAE
(Pyrexia occurring within 24 h of surgery was considered an AE
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TABLE 4 | Overall summary of tolerability/adverse events for ITT safety population.
Patients included Treatment group
Measure of toleration category 0.3 µg/kg/min 1 µg/kg/min 2 µg/kg/min 3 µg/kg/min Total
OVERALL
Number of patients 50 49 53 51 203
N (%) of Patients with at least one TEAE 50 (100.0%) 49 (100.0%) 53 (100.0%) 51 (100.0%) 203 (100.0%)
N (%) of Patients with at least one TESAE 5 (10.0%) 4 (8.2%) 5 (9.4%) 4 (7.8%) 18 (8.9%)
N (%) of Patients with TEAE leading to study drug withdrawal 19 (38.0%) 18 (36.7%) 13 (24.5%) 16 (31.4%) 66 (32.5%)
N (%) OF PATIENTS WITH TEAE BY SEVERITY
Mild 8 (16.0%) 10 (20.4%) 7 (13.2%) 8 (15.7%) 33 (16.3%)
Moderate AE 19 (38.0%) 19 (38.8%) 20 (37.7%) 15 (29.4%) 73 (36.0%)
Severe AE 23 (46.0%) 20 (40.8%) 26 (49.1%) 28 (54.9%) 97 (47.8%)
N (%) OF PATIENTS WITH TEAE BY RELATIONSHIP TO STUDY DRUG
Probably related 29 (58.0%) 32 (65.3%) 40 (75.5%) 36 (70.6%) 137 (67.5%)
Possibly related 12 (24.0%) 6 (12.2%) 2 (3.8%) 9 (17.6%) 29 (14.3%)
Probably not related 1 (2.0%) 5 (10.2%) 0 (0.0%) 3 (5.9%) 9 (4.4%)
Not related 8 (16.0%) 6 (12.2%) 11 (20.8%) 3 (5.9%) 28 (13.8%)
N (%) of deaths 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
TEAE, treatment-emergent adverse event; TESAE, treatment-emergent serious adverse event.
At each level of summarization, patients reporting more than one AE were counted only once under the strongest relationship and/or severity.
Neonates, birth to < 30 days; infant, 30 days to < 2 years; preschool, 2 years to < 6 years; school age, 6 years to < Tanner stage III; adolescent, Tanner stage III to < 17 years.
only if it was severe, because it is a condition associated with
surgical procedures).
We performed co-oximetry on arterial blood gas samples
and measured serum methemoglobin, lactate concentrations,
central venous oxygen saturation (in patients with an indwelling
central venous catheter), whole blood cyanide concentrations,
and plasma and urine thiocyanate concentrations. We also
assessed acid-base status. No cyanide toxicity was reported and
no measureable cyanide levels were detected.
Discussion
We performed a randomized, double-blind, parallel-group,
dose-ranging, effect-controlled, multicenter study to examine
the effects of SNP in pediatric patients requiring controlled
hypotension during a surgical or medical procedure. The goals of
the study were to prove the efficacy of SNP in various pediatric
age groups and to assess the safety of SNP administration
in pediatric patients requiring controlled reduction of blood
pressure. In addition, analysis of the data was designed to
establish the starting and maximum infusion rates that afford
optimum blood pressure control and a safe dosing regimen in
pediatric patients.
The following results describe the relationship between SNP
dose and changes in blood pressure in pediatric patients:
1. Administration of SNP resulted in statistically significant
reductions in MAP from baseline 30min after the initial start
of blinded study drug infusion for each of the SNP doses (0.3,
1, 2, and 3µg/kg/min).
2. A dose response for changes in MAP from baseline
determined within 30min of blinded study drug infusion
was observed in the ITT population as a general trend,
suggesting larger mean reductions with increasing SNP doses
(0.3–2µg/kg/min). However, the dose response should not be
considered linear because the SNP dose increases were not
equidistant. The maximum effect on change in MAP from
baseline at 30min after the infusion started was generally
observed at the 2-µg/kg/min SNP dose. The effect of the 3-
µg/kg/min SNP dose on MAP was less than that observed
with the 1- and 2-µg/kg/min dose. This was an unexpected
finding that could be due to the protocol design, which
may have selected for non-responders, as evidenced by the
number of ITT patients in the 2- and 3-µg/kg/min SNP dose
groups (13, 23.6%; and 18, 35.3%) compared with those in the
0.3- and 1-µg/kg/min SNP dose groups (38, 74.5%; and 23,
46.9%).
3. Overall, 98.5% of the patients achieved target MAP during
therapy. The majority of patients (72.9%) first achieved target
MAP during the blinded study drug period.
Our study’s safety results included the following: 18 patients
(8.9%) experienced one or more treatment-emergent SAEs.
Vascular disorders were the most common study-drug-related
TEAEs (>5% overall) and comprised the most common severe,
specific drug-related TEAEs. Hypotension was the AE that led
to the most study drug withdrawals. No patients experienced
TEAEs leading to study discontinuation and no deaths occurred
during the study.
An enormous safety concern is cyanide poisoning, but it
can be addressed. One way the development of poisoning
happens is as follows: The metabolism of SNP in red blood cells
(RBCs) results in the production of 5 molecules of cyanide,
one of which is then converted to thiocyanate (SCN) or is
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bound to methemoglobin to form cyanomethemoglobin. This
conversion occurs enzymatically via two sulfur transferase
systems: (1) rhodanase (the primary pathway) and (2) beta-
mercaptopyruvate-cyanide sulfurtransferase (the secondary
pathway). Rhodanase is ubiquitous in the body but highly
concentrated in the liver. Rhodanase catalyzes the transfer
of sulfur from a donor molecule such as sodium thiosulfate
(NaS2O3) to cyanide, to form SCN, which is subsequently
eliminated in the urine, where it serves as a marker of cyanide
exposure. However, this conversion is limited by the availability
of sulfur donor molecules. A life-saving intervention in the event
of possible acute cyanide intoxication is to provide the patient
exogenous sulfur donors such as Na2S2O3 (Pasch et al., 1983;
Cole and Vesey, 1987).
Despite the widespread use of SNP, there is a
paucity of information on its safety, efficacy, and
pharmacokinetic/pharmacodynamic (PK/PD) relationships
in children. Davies et al. and Bennett and Abbott described their
retrospective experience with SNP used to induce deliberate
hypotension in small cohorts of children (Davies et al., 1975;
Bennett and Abbott, 1977). Both observed that younger patients
required more SNP than older ones to achieve comparable
degrees of blood pressure control. In their small retrospective
cohort, Bennett and Abbott recommended that doses of
10µg/kg/min were necessary to achieve satisfactory blood
pressure response. Davies et al described three possible responses
to SNP administration in children: (1) a constant response to
“conventional” doses < 3mg/kg, (2) a tachyphylactic response
characterized by continuously escalating dose requirement
(>3mg/kg) to achieve a satisfactory blood pressure, and
(3) resistance to the blood pressure lowering effects of the
drug (Davies et al., 1975). Yaster et al. compared SNP and
nitroglycerine for inducing hypotension in a group of 14
adolescents (Yaster et al., 1986). They found that doses of
SNP between 6 and 8µg/kg/min were superior to doses of
nitroglycerine at any dose for reliably inducing hypotension for
children and adolescents undergoing scoliosis, craniofacial, or
hepatic surgery.
Hersey et al. performed a randomized trial comparing SNP
to the dihydropyridine calcium-channel antagonist nicardipine
in 20 healthy adolescents with idiopathic scoliosis undergoing
spinal fusion (Hersey et al., 1997), and they easily obtained
target blood pressures in both groups and operating conditions
were comparable. They found that time-to-restoration of baseline
blood pressure after termination of the infusion was significantly
longer in the nicardipine group than in the SNP group, but,
interestingly, blood loss was significantly greater in the SNP
group. Details on SNP dose requirements were not provided.
Przybylo et al. described cyanide and SCN blood levels in 10
children who received SNP at doses up to 10µg/kg/min (mean
infusion rate 6µg/kg/min) while undergoing cardiopulmonary
bypass for repair of complex congenital cardiac defects (Przybylo
et al., 1995). Cyanide levels rose as a function of time while
SNP was infused and rapidly fell when SNP was discontinued.
Despite the fact that some children demonstrated plasma cyanide
levels above the generally accepted threshold of 0.5µg/mL,
no patients developed clinically apparent toxicity. Kazim et al.
questioned the validity of the results of Przybylo et al’s study
because of the cyanide assay methods used (Kazim et al.,
1996). Linakis et al. retrospectively examined physician-ordering
practices for blood cyanide levels in children receiving SNP
(Linakis et al., 1991). They sought to determine how the
laboratory determinations were used to monitor patients and
if there was clinically apparent toxicity in children found to
have cyanide concentrations exceeding the “normal” limit of
0.5µg/mL. They found poor correlation between blood cyanide
concentration and dose or duration of therapy in patients whose
cyanide levels were “toxic.” Thiocyanate determinations were
normal and no child manifested signs or symptoms of cyanide
toxicity. They concluded that further pediatric studies were
needed.
On the basis of this study’s efficacy and safety data, we make
several recommendations:
1. A reasonable starting dose of SNP in pediatric patients
requiring deliberate induced hypotension is 0.3µg/kg/min;
in our study the mean infusion rate was approximately
1µg/kg/min.
2. Clinicians should increase the infusion rate to achieve the
desired reduction in blood pressure.
3. Because our data demonstrate wide variability in patient
responses to SNP, especially in regard to baseline MAP, basal
metabolic rate, and age, clinicians should use their experience
and the patient’s clinical situation as a basis for determining
both the starting and maintenance infusion rates.
4. Given that SNP is titrated to MAP response in most
situations, SNP dosing is already implicitly individualized.
However, modeling hemodynamic responses suggests ways
to more rapidly achieve target MAP endpoints and also
suggests that an algorithm-guided approach as opposed to the
currently employed empirical dose-titration approach may be
desirable.
In summary, individual patient dosing guidance must reflect
both the target and the population.
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